欢迎各位投资者参加华安医药联合录影中举办的夏季线上策略会本场会议主持人是华安医药首席唐国超老师本场是上市公司智云健康的交流很荣幸能够邀请到了公司领导CFO许总和IR李总来跟我们一起交流我们本场交流主要分为公司介绍和问答环节两个部分首先有请公司领导李总用20到30分钟的时间 对公司的一个新情况最新进展等做一个讲解有请公司领导好的 谢谢怀恩医药的李老师那我们就开始先做公司的介绍 那先跟大家讲一下那均匀健康呢是现在中国最大的这个数字化慢病管理的平台那我们公司业务呢是从2014年就是公司成立然后从2016年正式的开始进入慢病管理这个这个2B的这个行业来开始做的 那大家可以看到这张图呢就主要跟大家展示了我们现在的商业模式其实一句话来概括的话呢就是我们通过了两个SaaS的平台一边是医院的一个医会慢病管理SaaS一个是药店的药店问诊SaaS通过这两个平台呢一边粘住了医院一边粘住了药店也增加了这个整个的医疗就慢病管理相关的参与方的这个粘性提高了整个生态的这个医疗生态的效率 那么我们呢其实从这张图上我们可以这个分板块来讲那首先呢就是我们最大的一个板块是收入占比超过75%以上的就是我们的院内解决方案就是医院相关的这个板块那么 我 ...

欢迎各位投资者参加华安医药联合录影中举办的夏季线上策略会本场会议主持人是华安医药首席唐国超老师本场是上市公司智盈健康的交流很荣幸能够邀请到了公司领导CFO许总和IR李总来跟我们一起交流我们本场交流主要分为公司介绍和问答环节两个部分首先有请公司领导李总用20到30分钟的时间 对公司的一个经营情况最新进展等做一个讲解有请公司领导好的 谢谢怀恩医药的李老师那我们就开始先做公司的介绍 那先跟大家讲一下那志云健康呢是现在中国最大的这个数字化慢病管理的平台那我们公司业务呢是从2014年就是公司成立然后从2016年正式的开始进入慢病管理这个这个2B的这个行业来开始做的 那大家可以看到这张图呢就主要跟大家展示了我们现在的商业模式其实一句话来概括的话呢就是我们通过了两个SaaS的平台一边是医院的一个医会慢病管理SaaS一个是药店的药店问诊SaaS通过这两个平台呢一边粘住了医院一边粘住了药店也增加了这个整个的医疗就慢病管理相关的参与方的这个粘性提高了整个生态的这个医疗生态的效率 那么我们呢其实从这张图上我们可以这个分板块来讲那首先呢就是我们最大的一个板块是收入占比超过75%以上的就是我们的院内解决方案就是医院相关的这个板块那么 ...

智云健康240523华安原文 2024年05月23日11:22 发言人100:01 进入外面管理to b的这个行业来开始做的那大家可以看到这张图就主要跟大家展示了我们现在的商业模 式。其实一句话来概括的话，就是我们通过了两个size的平台。一边先是医院的一个医会慢病管 理sars，一个是药店的药店问诊sars。通过这两个平台，一边粘住了医院，一边粘住了药店，也增加了 整个的医疗慢病管理相关的参与方的年性，提高了整个生态的医疗生态的效率。 发言人100:33 我们其实从这张图上我们可以分板块来讲。首先我们最大的一个板块是收入占比超过75%以上的，就是 我们的院内解决方案，就是医院相关的这个板块。我们我们为什么要来做医院这个事情？其实大家在国 内的话都知道，中国整个的一个医疗，就是以这个公立医院为主导来进行的。所以说，如果你真正的要 去触达这个医疗的核心，你就必须要以医院为先去做这个事。我们从2016年来做这个事情的时候，就意 识到了这一点。所以我们也是一直确立是以医院为先，作为我们的这战略来开展业务的。 发言人101:16 关注公众号/知识星球：股市调研 发言人101:43 在医院端的话，其实首先我们就是要在医 ...

智[T云able健_S康tock（Na 9m 9eR 5p 5tT .y Hpe K] ） 公司研究/公司深度 深耕数字化慢病领域，三大解决方案并行发展 投资评级：买入（首次） 主要观点： [Table_Rank] [T深ab耕le_数S字um化m慢ar病y]领域，逐步迎来收获期 报告日期： 2024-05-13 智云健康科技集团是中国最大的数字化慢病管理解决方案提供 [收Ta盘bl价e_（Ba元se）Data] 3.19 商，2014年在杭州创办，2016年推出中国第一个针对慢病管理 近12个月最高/最低（元） 6.85/2.11 的医院SaaS产品。历经多轮境内外股权融资，公司已初具规模， 总股本（百万股） 587 逐步进入收获期，2023年集团平台注册医生达10.3万人，注册 流通股本（百万股） 587 用户约3,100万人。2019年-2023年，公司营业收入从5.24亿 流通股比例（%） 100% 元增长至36.91亿元，盈利能力呈持续增长态势。 总市值（亿元） 19 2023年3大板块同步发力。 流通市值（亿元） 19  院内解决方案板块：安装SaaS医院数量2,719家,+5.9%YoY； ...

團 ClouDr Group Limited* 智 雲 健 康 ClouDr Group Limited 智雲健康科技集團* 科 技 集 (Incorporated in the Cayman Islands with limited liability) Stock Code : 9955 Annual Report 年報 2023 * For identification purpose only ClouDr Group Limited 智雲健康科技集團* （於開曼群島註冊成立的有限公司） 股份代號 : 9955 年 報 Annual Report 2023 2023 * 僅供識別 目錄 | --- | --- | |--------------------------|-------| | 公司資料 | 2 | | 財務概要 | 4 | | 業務回顧與展望 | 5 | | 管理層討論及分析 | 14 | | 董事會報告 | 21 | | 董事及高級管理層 | 38 | | 其他資料 | 44 | | 企業管治報告 | 53 | | 獨立核數師報告 | 70 | | 綜合損益表 | 75 | | 綜合損 ...

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 3,690.5 million, representing a year-on-year increase of 23.5%[2] - Gross profit for the same period was RMB 909.4 million, up 14.8% compared to the previous year[2] - The adjusted net loss (non-IFRS) narrowed to RMB 75.1 million, a decrease of 77.4% year-on-year[2] - The company recorded a net loss of approximately RMB 327.3 million for the year ended December 31, 2023, a reduction of 80.7% from RMB 1,692.2 million for the previous year[31] - Operating loss decreased by 46.9% from approximately RMB 591.6 million to approximately RMB 314.2 million, primarily due to significant revenue growth and increased operating leverage[27] - The gross margin for chronic disease management solutions improved to 28.1%, up from 20.7% in 2022[14] - The company incurred a pre-tax loss of RMB 327,326,000 in 2023, a decrease from a loss of RMB 1,693,643,000 in 2022[76] Revenue Breakdown - Revenue from hospital solutions reached RMB 2,873.1 million, reflecting a growth of 31.5%[2] - Revenue from pharmacy solutions reached RMB 658,583,000, a 6.9% increase from RMB 615,812,000 in 2022[11] - Revenue from subscription solutions (precision marketing) revenue decreased by 13.4% to RMB 467.2 million[2] - The newly introduced P2M solutions generated revenue of RMB 101.2 million, as it was not recorded in the previous year[2][3] - Revenue from in-hospital solutions reached RMB 2,873.1 million, a growth of 31.5% from RMB 2,184.5 million in the previous year[8] - Revenue from pharmacy subscription solutions was RMB 59.1 million, a growth of 7.2% from the previous year[10] Strategic Initiatives - The company is focusing on a "patient-to-industry" (P2M) strategy to enhance profitability through strategic partnerships with pharmaceutical companies[4] - The company aims to leverage AI innovations to improve healthcare ecosystem efficiency and enhance digital infrastructure for chronic disease management[4] - The company plans to focus on enhancing its hospital SaaS infrastructure and expanding its self-operated product pipeline under the P2M strategy[18] - The company aims to expand its hospital SaaS network and strengthen relationships with hospitals to enhance commercialization opportunities[6] Operational Metrics - As of December 31, 2023, 2,719 hospitals have installed the company's Zhiyun Yihui SaaS, an increase of 152 hospitals or 5.9% compared to the previous year[9] - The number of pharmaceutical companies contracted for precision marketing services increased by 50.0% to 39 as of December 31, 2023, compared to 26 the previous year[9] - The total number of SKUs in cooperation reached 59, marking a 73.5% increase from 34 SKUs the previous year[9] - The number of pharmacy stores using the Zhiyun Wenjin SaaS reached 219,716, an increase of 26,389 stores or 13.7% from the previous year[10] - The number of registered users for chronic disease management solutions increased to approximately 31.2 million, up 9.5% from 28.5 million in 2022[14] - The total number of full-time employees as of December 31, 2023, was 1,522, with over 3,000 flexible staff supporting business penetration in lower-tier cities[42] Cost and Expenses - Research and development expenses decreased from approximately RMB 114.8 million to approximately RMB 88.0 million, reflecting improved efficiency and reduced R&D requirements for mature products[26] - The ratio of sales and marketing expenses to revenue decreased from 29.2% to 21.5%, indicating improved operational efficiency[24] - The total personnel-related costs for the year ended December 31, 2023, amounted to approximately RMB 1,007.9 million, an increase from RMB 990.3 million for the year ended December 31, 2022[43] - Full-time employee costs for the year ended December 31, 2023, were approximately RMB 629.4 million, compared to RMB 610.2 million for the previous year[43] - Flexible employee costs for the year ended December 31, 2023, were approximately RMB 378.5 million, slightly down from RMB 380.1 million in the previous year[43] Financial Position - Cash and cash equivalents as of December 31, 2023, were approximately RMB 243.4 million, slightly down from RMB 249.7 million in 2022[36] - The debt-to-asset ratio remained stable at 33.2% as of December 31, 2023, compared to 33.6% in 2022[39] - The company’s total equity decreased to RMB 1,765,306 thousand as of December 31, 2023, from RMB 1,881,375 thousand in 2022, a decline of approximately 6.2%[59] - The company’s capital reserves increased significantly due to the proceeds from the share issuance, amounting to approximately RMB 472,020 thousand after deducting issuance expenses[87] Compliance and Governance - The company has complied with all applicable corporate governance codes as of December 31, 2023, with some deviations noted regarding the roles of the Chairman and CEO[46] - The audit committee reviewed the audited consolidated financial statements for the year ended December 31, 2023, and found them compliant with relevant accounting standards[48] - The company has not applied any new standards or interpretations that have not yet come into effect during the accounting period, ensuring compliance with the latest international financial reporting standards[63] Future Outlook - Future growth in chronic disease management solutions is expected to be driven by a favorable business model and increased commercialization efforts[19] - The company plans to meet its working capital needs through cash generated from operations and funds raised from capital markets, with no plans for significant external financing[36]

Revenue Growth - Revenue increased by 30.6% to RMB 1,802,564 thousand in the first half of 2023 compared to RMB 1,379,723 thousand in the same period of 2022[5] - Revenue from in-hospital solutions increased by 30.1% to RMB 1,404,032 thousand in the first half of 2023 compared to RMB 1,079,609 thousand in the first half of 2022[6] - Revenue from pharmacy solutions surged by 58.0% to RMB 325,032 thousand in the first half of 2023 from RMB 205,778 thousand in the first half of 2022[6] - Revenue from value-added solutions grew by 43.7% to RMB 1,429,137 thousand in the first half of 2023 from RMB 994,687 thousand in the first half of 2022[6] - Total revenue for the first half of 2023 reached RMB 1,802.6 million, a year-on-year increase of 30.6%[10] - Revenue from in-hospital solutions increased by 30.1% to RMB 1,404.0 million in the first half of 2023[14] - Revenue from value-added solutions grew by 39.0% to RMB 1,132.0 million in the first half of 2023[14] - Revenue from pharmacy solutions reached RMB 325.032 million, a 58.0% increase from RMB 205.778 million[18] - Revenue from value-added solutions grew to RMB 297.104 million, up 65.0% from RMB 180.068 million[18] - Revenue increased by 30.6% from RMB 1,379.7 million in H1 2022 to RMB 1,802.6 million in H1 2023, driven by strong growth in hospital and pharmacy solutions[25] - Hospital solutions revenue grew by 30.1% from RMB 1,079.6 million in H1 2022 to RMB 1,404.0 million in H1 2023, due to increased paid hospitals and enhanced digital marketing services with pharmaceutical companies[25] - Pharmacy solutions revenue surged by 58.0% from RMB 205.8 million in H1 2022 to RMB 325.0 million in H1 2023, driven by increased paid pharmacies and enriched subscription services[25] - Revenue for the six months ended June 30, 2023, increased to RMB 1,802,564 thousand, up 30.6% from RMB 1,379,723 thousand in the same period in 2022[73] - Total revenue for the six months ended June 30, 2023, was RMB 1,802,564 thousand, compared to RMB 1,379,723 thousand in the same period of 2022, representing a 30.6% year-over-year increase[88] - Revenue from the "In-Hospital Solutions" segment, specifically the "Value-Added Solutions" category, increased to RMB 1,132,033 thousand in 2023 from RMB 814,619 thousand in 2022, a 39% growth[91] - Revenue from the "Pharmacy Solutions" segment, specifically the "Value-Added Solutions" category, rose to RMB 297,104 thousand in 2023 from RMB 180,068 thousand in 2022, a 65% increase[91] Profit and Loss - Gross profit rose by 22.7% to RMB 473,569 thousand in the first half of 2023 from RMB 386,014 thousand in the first half of 2022[5] - Operating loss decreased by 41.5% to RMB 154,309 thousand in the first half of 2023 from RMB 263,941 thousand in the first half of 2022[5] - Net loss significantly reduced by 87.1% to RMB 159,576 thousand in the first half of 2023 from RMB 1,234,679 thousand in the first half of 2022[5] - Adjusted net loss (non-IFRS measure) decreased by 60.2% to RMB 58,863 thousand in the first half of 2023 from RMB 147,977 thousand in the first half of 2022[5] - Gross profit for the first half of 2023 was RMB 473.6 million, up 22.7% year-on-year[10] - Non-IFRS adjusted net loss narrowed to RMB 58.9 million, a significant year-on-year reduction of 60.2%[10] - Gross margin for value-added solutions improved to 15.7%, up 3.4 percentage points year-on-year[14] - Gross profit rose from RMB 386.0 million in H1 2022 to RMB 473.6 million in H1 2023, while gross margin declined from 28.0% to 26.3% due to a shift in revenue mix[27] - Hospital solutions gross margin decreased from 31.3% in H1 2022 to 30.2% in H1 2023, primarily due to the revenue mix between subscription and value-added solutions[27] - Pharmacy solutions gross margin dropped from 15.0% in H1 2022 to 10.5% in H1 2023, influenced by pricing strategies and inventory discounts[28] - Operating loss decreased by 41.5% from RMB 263.9 million in H1 2022 to RMB 154.3 million in H1 2023, driven by significant revenue growth and improved operating leverage[32] - Net loss for the period decreased to RMB 159,576 thousand, a substantial improvement from RMB 1,234,679 thousand in the first half of 2022[73] - Basic and diluted loss per share improved to RMB 0.29, compared to RMB 11.94 in the same period last year[73] - Net loss for the period amounted to RMB 1,234,679 thousand[81] - The company reported a basic loss per share of RMB 156 million for the six months ended June 30, 2023, compared to RMB 1,231 million for the same period in 2022[99] Expenses and Costs - R&D expenses decreased from RMB 79.0 million in H1 2022 to RMB 40.4 million in H1 2023, reflecting efficiency improvements and reduced development needs for mature SaaS platforms[31] - Sales and marketing expenses increased by 6.7% from RMB 426.2 million in H1 2022 to RMB 454.9 million in H1 2023, with employee-related costs accounting for over 81% of the total[29] - Total expenses for sales and marketing were RMB 1,227 million, R&D expenses were RMB 127 million, and general and administrative expenses were RMB 67 million[45] - Employee costs for the six months ended June 30, 2023, were RMB 283,592 thousand, slightly up from RMB 282,176 thousand in the same period of 2022[94] - Inventory costs increased to RMB 1,261,046 thousand in 2023 from RMB 915,359 thousand in 2022, a 37.8% rise[96] - The company's pre-tax loss for the six months ended June 30, 2023, included financing costs of RMB 6,441 thousand, up from RMB 3,557 thousand in 2022[93] - The company's income tax expense for the six months ended June 30, 2023, was RMB (1,174) thousand, compared to RMB (661) thousand in 2022[97] Cash Flow and Financial Position - Cash and cash equivalents decreased from RMB 249.7 million as of December 31, 2022, to RMB 194.4 million as of June 30, 2023, while financial assets measured at fair value stood at RMB 425.0 million[41] - The company's bank and other loans increased from RMB 192.5 million as of December 31, 2022, to RMB 269.1 million as of June 30, 2023, with an annual interest rate ranging from 3.6% to 5.5%[41] - The company's asset-liability ratio increased from 33.6% as of December 31, 2022, to 35.6% as of June 30, 2023, mainly due to an increase in bank loans[41] - Total assets decreased slightly to RMB 1,878,694 thousand as of June 30, 2023, from RMB 1,950,411 thousand at the end of 2022[75] - Cash and cash equivalents stood at RMB 194,406 thousand as of June 30, 2023, down from RMB 249,674 thousand at the end of 2022[75] - Trade receivables and bills increased to RMB 789,922 thousand, up from RMB 758,533 thousand at the end of 2022[75] - Operating cash outflow for the period was RMB 54,349 thousand[84] - Investment activities resulted in a net cash outflow of RMB 48,811 thousand[84] - Financing activities generated a net cash inflow of RMB 46,412 thousand[85] - Cash and cash equivalents decreased by RMB 56,748 thousand during the period[85] - Cash and cash equivalents at the end of the period stood at RMB 194,406 thousand[85] - The company's inventory of finished goods was RMB 215.8 million as of June 30, 2023, compared to RMB 224.8 million as of December 31, 2022[106] - Trade receivables and notes receivable amounted to RMB 789.9 million as of June 30, 2023, compared to RMB 758.5 million as of December 31, 2022[107] - The company's prepayments, deposits, and other receivables totaled RMB 548.1 million as of June 30, 2023, compared to RMB 479.4 million as of December 31, 2022[112] - The company's expected credit loss provision for other receivables was RMB 16.0 million as of June 30, 2023, compared to RMB 11.9 million as of December 31, 2022[113] - Financial products held by the company as of June 30, 2023, amounted to RMB 424,989 thousand, with an expected annual return rate ranging from 1.20% to 5.67%[114] - Trade payables increased to RMB 246,856 thousand as of June 30, 2023, from RMB 120,800 thousand at the end of 2022[116][117] - Other payables and accrued expenses decreased to RMB 330,854 thousand as of June 30, 2023, from RMB 459,870 thousand at the end of 2022[118] Employee and Compensation - The company had 1,489 employees as of June 30, 2023, with 453 in Hangzhou, 152 in Shanghai, and 884 in other offices across China, and engaged over 9,000 hospitals and 200,000 pharmacies[44] - Total employee-related costs for the six months ended June 30, 2023, were approximately RMB 517.8 million, compared to RMB 480.9 million for the same period in 2022[46] - Full-time employee costs for the six months ended June 30, 2023, were approximately RMB 283.6 million, compared to RMB 282.2 million for the same period in 2022[46] - Flexible personnel costs for the six months ended June 30, 2023, were approximately RMB 234.2 million, compared to RMB 198.7 million for the same period in 2022[46] - The company has adopted the Pre-IPO Equity Incentive Plan and Post-IPO Share Incentive Plan to motivate employees[46] - The company conducts quarterly performance evaluations and provides feedback to employees to ensure competitive and fair compensation[46] - The company offers customized training programs to employees, including online training and internal courses led by senior employees or external consultants[46] Shareholder and Equity Information - The company's Chairman and CEO roles are currently held by the same individual, Mr. Kuang Ming, to ensure consistent leadership and strategic planning[48] - The company has adopted the Corporate Governance Code and complies with its principles, except for the separation of Chairman and CEO roles[48] - The company has granted a total of 61,564,335 restricted share units under the Pre-IPO Share Incentive Plan, with 13,924,965 units vested and transferred during the reporting period[52] - As of June 30, 2023, 45,611,321 reward shares were available for grant under the Post-IPO Share Reward Plan, with no shares granted during the reporting period[54] - The maximum number of new shares that can be issued under the Post-IPO Share Reward Plan is 58,703,821, representing approximately 10% of the company's issued share capital at the time of listing[55] - Mr. Kuang, the Executive Director and CEO, holds a 22.23% beneficial interest in the company, including 130,481,685 shares through controlled entities and direct holdings[59] - The company's total issued share capital as of June 30, 2023, is 587,038,219 shares[61] - Mr. Kuang was granted 2,000,000 restricted share units under the Pre-IPO Share Incentive Plan on December 30, 2022, which remain unvested as of June 30, 2023[61] - The company's four highest-paid individuals (excluding Mr. Kuang) were granted 25,947,715 restricted share units between 2018 and 2022, with 5,000,000 units vested during the reporting period[52] - The company's other employees were granted a total of 28,366,785 restricted share units between 2015 and 2022, with 8,924,965 units vested during the reporting period[52] - The weighted average market price of the shares granted under the Pre-IPO Share Incentive Plan during the reporting period was HK$7.30 per share[52] - The company's Post-IPO Share Reward Plan allows for the grant of up to 3% of the total issued shares during any given period[54] - Hengtai Trust (Hong Kong) Limited holds a 23.96% interest in the company, with 140,647,164 shares[63] - Data Vantage Development Limited holds a 15.23% interest in the company, with 89,414,780 shares[63] - HaoYuan Health Limited holds a 15.23% interest in the company, with 89,414,780 shares[63] - Prime Forest Assets Limited holds an 8.73% interest in the company, with 51,232,384 shares[63] - China Merchants Bank and its subsidiaries collectively hold a 5.47% interest in the company, with 32,138,712 shares[63] Strategic Plans and Investments - The company plans to focus on expanding its hospital and pharmacy networks, investing in AI-driven medical innovation, and enhancing strategic partnerships and acquisitions[24] - The total net proceeds from the global offering were approximately HKD 425.7 million, with 60% allocated for business expansion, 25% for enhancing medical knowledge and technological capabilities, 5% for strategic partnerships and acquisitions, and 10% for working capital and general corporate purposes[67][68] - As of June 30, 2023, HKD 221.4 million remained unutilized for business expansion, with HKD 10.7 million utilized in the first half of 2023[68] - HKD 92.1 million remained unutilized for enhancing medical knowledge and technological capabilities, with HKD 5.1 million utilized in the first half of 2023[68] - HKD 18.3 million remained unutilized for strategic partnerships and acquisitions, with HKD 3.0 million utilized in the first half of 2023[68] - HKD 32.9 million remained unutilized for working capital and general corporate purposes, with HKD 5.4 million utilized in the first half of 2023[68] Subsidiaries and Affiliates - The company's wholly-owned subsidiary, Hangzhou Zhiyun Huiyi Technology Co., Ltd., was established on December 30, 2020, in China[141] - Chengdu Zhiyun Internet Hospital Co., Ltd., a subsidiary of the company, was registered on June 18, 2021, in China[141] - The company's consolidated affiliated entities include Hangzhou Kangming, Chengdu Zhiyun Internet Hospital, and Tianjin Zhiyun, whose financial accounts are consolidated under contractual arrangements[141] - The company's consolidated affiliated entity, Tianjin Zhiyun Comprehensive Clinic Co., Ltd., was established on March 26, 2021, in China[143] Financial Instruments and Fair Value - Financial products held by the company as of June 30, 2023, amounted to RMB 424,989 thousand, with an expected annual return rate ranging from 1.20% to 5.67%[114] - The company's financial assets are classified as Level 1 in the fair value hierarchy, with no Level 2 or Level 3 classifications[126] - The fair value of financial instruments classified as Level 3 under the fair value hierarchy was RMB 45,399 thousand for wealth management products and RMB 378,102 thousand for fund management products as of December 31, 2022[130] - The company's financial assets classified as Level 3 under the fair value hierarchy are valued using the discounted cash flow method, with a significant unobservable input being the expected rate of return[131] - A 0.5% increase/decrease in the estimated weighted average expected rate of return would result in a decrease/increase of approximately RMB 1,227,759 in the company's pre-tax loss for the six months ended June 30, 2023[131] - The balance of financial products issued by financial institutions classified as Level 3 under the fair value hierarchy increased from RMB 28,000 thousand as of January 1, 2023, to RMB 424,989 thousand as of June 30, 2023[133] - The company's convertible redeemable preferred shares are classified as Level 3 under the fair value hierarchy[133] - The fair value of the company's convertible redeemable preferred shares was RMB 10,378,582 thousand as of June 30, 2022[136] Related Party Transactions - The company had significant related party transactions, including guarantees provided by related parties for bank and other loans amounting to RMB 18,000 thousand as of June 30, 2023[139] - The company acquired non-controlling interests for RMB 25,

Financial Performance - Revenue for the six months ended June 30, 2023, reached RMB 1,802,564 thousand, representing a 30.6% increase compared to RMB 1,379,723 thousand in the same period of 2022[2] - Gross profit for the same period was RMB 473,569 thousand, up 22.7% from RMB 386,014 thousand year-on-year[2] - The adjusted net loss (non-IFRS measure) decreased by 60.2% to RMB 58,863 thousand from RMB 147,977 thousand in the previous year[2] - Total revenue for the six months ended June 30, 2023, reached RMB 1,802.6 million, representing a year-on-year growth of 30.6%[9] - Gross profit for the same period was RMB 473.6 million, an increase of 22.7% year-on-year[9] - Non-IFRS adjusted net loss narrowed to RMB 58.9 million, a significant reduction of 60.2% year-on-year[9] - Revenue increased by 30.6% from approximately RMB 1,379.7 million for the six months ended June 30, 2022, to approximately RMB 1,802.6 million for the six months ended June 30, 2023, driven by strong growth in both hospital and pharmacy solutions[23] - Revenue from hospital solutions rose by 30.1% to approximately RMB 1,404.0 million, attributed to an increase in the number of paying hospitals and enhanced collaborations with pharmaceutical companies[23] - Revenue from pharmacy solutions surged by 58.0% to approximately RMB 325.0 million, mainly due to an increase in paid pharmacies benefiting from upgraded supply chain capabilities[23] Operational Highlights - The company's in-hospital solutions generated revenue of RMB 1,404,032 thousand, a 30.1% increase from RMB 1,079,609 thousand in the prior year[2] - The pharmacy solutions segment saw a significant revenue increase of 58.0%, reaching RMB 325,032 thousand compared to RMB 205,778 thousand in the same period last year[2] - The number of hospitals deploying the company's SaaS reached 2,658, an increase of 6.7% from 2,490 hospitals as of June 30, 2022[13] - The company signed contracts with 36 pharmaceutical companies for digital marketing services, a growth of 56.5% compared to 23 companies as of June 30, 2022[13] - The total number of cooperative SKUs reached 45, up 55.2% from 29 SKUs as of June 30, 2022[13] - The number of pharmacies deploying the pharmacy SaaS reached 200,431, an increase of 7.9% from 185,731 as of June 30, 2022[17] - The number of transaction customers for value-added solutions increased to 766, up 52.6% from 502 in the same period last year[17] Strategic Focus - The company is recognized as the largest provider of digital chronic disease management solutions in China, focusing on SaaS deployment in hospitals and pharmacies[4] - The company aims to leverage its position as a pioneer in building digital infrastructure for chronic disease management in the evolving digital economy[8] - The company continues to focus on the "hospital-first" strategy, showing strong growth momentum despite a relatively weak consumer recovery[9] - The company plans to continue expanding its hospital and pharmacy network and SaaS installations to strengthen its market position in chronic disease management[22] - The company aims to invest in product and technology innovation, focusing on medical artificial intelligence to enhance its service offerings[22] Cost and Expenses - Operating loss decreased by 41.5% to approximately RMB 154.3 million for the six months ended June 30, 2023, due to significant revenue growth and increased operating leverage[29] - Research and development expenses decreased from approximately RMB 79.0 million to approximately RMB 40.4 million, reflecting improved efficiency and reduced R&D requirements for mature SaaS products[28] - Sales and marketing expenses increased by 6.7% to approximately RMB 454.9 million, with the ratio of sales and marketing expenses to revenue decreasing from 29.1% to 24.1%[26] - Administrative expenses remained relatively stable at approximately RMB 147.6 million, with the ratio to revenue decreasing from 4.4% to 3.9%[27] - Personnel-related costs for the six months ended June 30, 2023, amounted to approximately RMB 517.8 million, an increase from RMB 480.9 million for the same period in 2022[45] Financial Position - Cash and cash equivalents as of June 30, 2023, were approximately RMB 194.4 million, down from RMB 249.7 million as of December 31, 2022[38] - Bank and other loans increased to RMB 269.1 million as of June 30, 2023, from RMB 192.5 million as of December 31, 2022[38] - The debt-to-asset ratio as of June 30, 2023, was 35.6%, up from 33.6% as of December 31, 2022, primarily due to increased bank loans[41] - The company's equity attributable to shareholders was RMB 1,780,405 thousand, a decrease from RMB 1,849,348 thousand at the end of 2022[59] - Current liabilities decreased to RMB 2,207,254 thousand from RMB 2,248,462 thousand, indicating improved liquidity management[57] Shareholder Information - The company did not recommend the distribution of an interim dividend for the six months ended June 30, 2023[3] - The audit committee reviewed the unaudited consolidated financial statements for the six months ended June 30, 2023, and found them compliant with relevant accounting standards[49] - The company has adopted a pre-IPO equity incentive plan and a post-IPO share incentive plan to motivate employees[45] - The interim results announcement and report for the six months ended June 30, 2023, will be sent to shareholders and published on the company's website at an appropriate time[105]

Financial Performance - Total revenue for 2022 reached RMB 2,988.1 million, a year-on-year increase of 70.1%[5] - Gross profit increased by 39.0% to RMB 792.1 million in 2022[5] - Operating loss decreased by 15.0% to RMB 591.6 million in 2022[5] - Net loss for the year improved by 59.3% to RMB 1,692.2 million in 2022[5] - Adjusted net loss (non-IFRS) decreased by 25.0% to RMB 332.8 million in 2022[5] - Revenue from in-hospital solutions increased by 71.6% to RMB 2,184.5 million in 2022[6] - Revenue from pharmacy solutions grew by 76.0% to RMB 615.8 million in 2022[6] - Revenue from personal chronic disease management solutions rose by 40.1% to RMB 187.8 million in 2022[6] - Subscription solutions revenue increased by 31.5% to RMB 594.5 million in 2022[6] - Value-added solutions revenue surged by 88.4% to RMB 2,205.8 million in 2022[6] - Total revenue increased by 70% to RMB 2,988 million in 2022, driven by strong growth in hospital and pharmacy solutions[26] - Revenue from hospital solutions grew by 72% to RMB 2,184.5 million in 2022, primarily due to increased SaaS penetration and collaboration with pharmaceutical companies[26] - Revenue from pharmacy solutions rose by 76% to RMB 615.8 million in 2022, driven by increased paid pharmacies and enhanced supply chain capabilities[26] - Overall gross profit increased by 39% from RMB 570 million in 2021 to RMB 792 million in 2022, while overall gross margin decreased from 32.4% to 26.5% due to changes in revenue structure between high-margin and low-margin businesses[28] - In-hospital solutions gross margin decreased from 37.2% in 2021 to 31.3% in 2022, with subscription solutions revenue growing by 34%, slower than hospital value-added solutions[28] - Pharmacy solutions gross margin decreased from 17.8% in 2021 to 11.4% in 2022, driven by revenue structure changes between subscription and value-added solutions[29] - Sales and marketing expenses increased by 18% from RMB 787.3 million in 2021 to RMB 933.2 million in 2022, but the ratio to revenue decreased from 41.5% to 29.2%[30] - Administrative expenses increased by 24.5% from RMB 269.6 million in 2021 to RMB 335.6 million in 2022, with the ratio to revenue decreasing from 5.8% to 4.3%[31] - R&D expenses decreased from RMB 236.2 million in 2021 to RMB 114.8 million in 2022, with the ratio to revenue dropping from 11.5% to 3.7%[32] - Operating loss decreased by 15.0% from RMB 695.9 million in 2021 to RMB 591.6 million in 2022, driven by revenue growth and improved operating leverage[33] - Net loss decreased by 59.3% from RMB 4,153.2 million in 2021 to RMB 1,692.2 million in 2022, primarily due to revenue growth, operating leverage, and changes in fair value of financial liabilities[37] - Adjusted net loss (non-IFRS) decreased from RMB 444.0 million in 2021 to RMB 332.8 million in 2022, with the adjusted net loss ratio improving from 25.3% to 11.1%[38][39] - Revenue for 2022 increased to RMB 2,988,056 thousand, up 70.1% from RMB 1,756,731 thousand in 2021[183] - Gross profit for 2022 was RMB 792,100 thousand, a 38.9% increase from RMB 570,024 thousand in 2021[183] - Operating loss for 2022 improved to RMB 591,563 thousand, compared to RMB 695,911 thousand in 2021[183] - Net loss for 2022 was RMB 1,692,221 thousand, a significant improvement from RMB 4,153,193 thousand in 2021[183] - Total comprehensive loss for 2022 was RMB 2,158,772 thousand, compared to RMB 4,021,261 thousand in 2021[186] Business Segments and Solutions - Revenue from in-hospital solutions increased by 71.6% to RMB 2,184.5 million in 2022[6] - Revenue from pharmacy solutions grew by 76.0% to RMB 615.8 million in 2022[6] - Revenue from personal chronic disease management solutions rose by 40.1% to RMB 187.8 million in 2022[6] - Subscription solutions revenue increased by 31.5% to RMB 594.5 million in 2022[6] - Value-added solutions revenue surged by 88.4% to RMB 2,205.8 million in 2022[6] - The company's hospital SaaS system, Zhiyun Medical Hub, has been installed in 2,567 hospitals, including 714 tertiary public hospitals and 1,092 secondary public hospitals, as of December 31, 2022[11] - The number of paid customers for the hospital subscription solutions increased by 73% to 26, with a total of 34 SKUs, and the annual recurring revenue reached RMB 416.8 million, representing 103% of the previous year's revenue[11] - The number of hospitals purchasing value-added solutions directly or indirectly increased by 34% to 2,818, with an annual recurring revenue of RMB 971.1 million, representing 112% of the previous year's revenue[12] - The hospital solutions segment revenue increased by 71.6% to RMB 2,184.5 million, with subscription solutions revenue growing by 33.9% to RMB 539.4 million and value-added solutions revenue surging by 89.1% to RMB 1,645.1 million[13] - The gross margin for hospital solutions decreased by 5.9 percentage points to 31.3%, while subscription solutions gross margin improved by 1.5 percentage points to 88.6%[13] - The number of pharmacies deploying the company's pharmacy SaaS system, Zhiyun Consultation, reached 193,327, covering over 33% of pharmacies in China, with 90,801 paid customers using the subscription solutions[16] - The pharmacy solutions segment revenue increased by 76.0% to RMB 615.8 million, with value-added solutions revenue growing by 86.3% to RMB 560.7 million[17] - The gross margin for pharmacy solutions decreased by 6.4 percentage points to 11.4%, while subscription solutions gross margin remained high at 95.2%[17] - The number of transaction customers for pharmacy value-added solutions increased by 42.8% to 975, with average revenue per customer growing by 30.5% to RMB 575,000[18] - The company's personal chronic disease management solution has 98,700 registered doctors and 28.5 million registered users as of December 31, 2022[19] - Revenue from personal chronic disease management solutions and others increased by 40.1% to RMB 187.767 million in 2022[20] - Revenue from chronic disease products surged by 62.7% to RMB 86.264 million in 2022[20] - The number of online prescriptions issued reached 169.6 million in 2022, a 10.5% increase from 2021[21] Corporate Governance and Leadership - The company's shares were included in the Hang Seng Index on February 24, 2023, and in the Shenzhen-Hong Kong Stock Connect program on March 13, 2023[22] - The company conducted real-world research on 11.1 million online antihypertensive treatment prescriptions, revealing that about half of hypertension patients have comorbidities[23] - The company established a strategic partnership with Baidu's AI chatbot "Wenxin Yiyan" to enhance AI technology in healthcare management solutions[24] - Li Jiacong, aged 41, serves as a non-executive director and audit committee member, bringing over 15 years of experience in law and finance[86] - Dr. Hong Weili, aged 53, is an independent non-executive director with extensive experience in financial and investment sectors, including roles at Huaren Cultural Group and Noah Holdings[87] - Zhang Saiyin, aged 43, is an independent non-executive director with a strong background in finance, having served as CFO at MINISO Group and various roles at China Resources[88] - Ang Khai Meng, aged 62, is an independent non-executive director with 37 years of experience in the healthcare industry, including leadership roles at Roche and Medtronic[88] - Xu Lili, aged 41, has been the CFO since October 2020, with over 16 years of financial management experience, including roles at Tongdao Liepin Group and General Electric[91] - Wang Jingxu, aged 54, has been the Vice President of Hospital Business and Development since August 2018, with 30 years of experience in the life sciences and pharmaceutical industries[92] - Mr. Li Gang, aged 42, has been the head of the company's technology department since March 2016, responsible for product and technology R&D[93] - Ms. Zuo Yinghui, aged 47, has been the Vice President of Supply Chain and Customer Service since January 2015, overseeing supply chain management and business expansion[93] - Ms. Liu Mengya, aged 34, has been the Co-Company Secretary and Senior Financial Director since October 2020, managing investor relations and financial operations[94] - Ms. Feng Huisen, aged 40, is the Co-Company Secretary and Senior Manager of Corporate Services at Tricor Services Limited, with over 15 years of experience in corporate secretarial services[95] - Mr. Zhang Saiyin resigned as Executive Director, Executive Vice President, and CFO of MINISO Group Holding Limited on January 31, 2023[96] - The company has adopted the principles and code provisions of the Corporate Governance Code and has complied with applicable code provisions since its listing on July 6, 2022[131] - The Board of Directors consists of five members, including one executive director, one non-executive director, and three independent non-executive directors[133] - The Chairman and CEO roles are held by Mr. Kuang, who is also the founder of the group, ensuring consistent internal leadership and effective strategic planning[135] - The company has established a Board Independence Assessment Mechanism to ensure strong independence and effective exercise of independent judgment[137] - All directors are subject to retirement by rotation, with Mr. Kuang and Mr. Li eligible for re-election at the upcoming annual general meeting[138] - The Audit Committee reviewed the audited consolidated financial statements for the year ended December 31, 2022, and confirmed compliance with applicable accounting principles, standards, and regulations[143] - The Audit Committee held two meetings during the reporting period to review the interim financial results for the six months ended June 30, 2022, and discussed audit plans, risk management, and internal control systems[143] - The Remuneration Committee held one meeting to review the compensation policies and remuneration for directors and senior management, including share awards and restricted share units[144] - The Remuneration Committee's report shows that 3 senior management members received compensation exceeding RMB 10,000,001, while 1 member received between RMB 5,000,001 and RMB 10,000,000, and 1 member received up to RMB 5,000,000[145] - The Nomination Committee held one meeting to review the structure, size, and composition of the Board, as well as the independence of independent non-executive directors[146] - The Nomination Committee considers diversity, character, qualifications, experience, and independence when selecting and recommending suitable director candidates[146] - The Board established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with written terms of reference outlining their roles and responsibilities[142] - The Audit Committee met with external auditors once during the reporting period without the presence of executive directors[143] - The Board ensures that all directors have full and timely access to company information and can seek independent professional advice when necessary[139] - The Board retains decision-making authority over key matters, including policy, strategy, budget, internal control, risk management, and significant transactions[139] - The company aims to appoint at least one female director to the board by December 2023 to enhance gender diversity[148] - Female employees accounted for 48% of the total workforce as of December 31, 2022[149] - The company will implement policies to ensure gender diversity in recruitment and develop female senior management and board succession candidates[148] - The board will consider setting measurable targets for implementing the board diversity policy and review progress periodically[148] - The nomination committee will review the board diversity policy to ensure its effectiveness[148] - The company prohibits any form of harassment or discrimination based on race, color, age, gender, sexual orientation, gender identity, disability, pregnancy, religion, political affiliation, veteran status, or union membership[149] - The company ensures equal opportunities in recruitment, training, development, promotion, and compensation regardless of gender, age, race, disability, or region[149] - The nomination committee is responsible for ensuring board diversity and will recommend suitable candidates based on various criteria including gender, age, cultural and educational background, professional qualifications, skills, knowledge, and industry experience[147] - The board has reviewed the company's corporate governance policies, training, and compliance with legal and regulatory requirements during the reporting period[152] - The board held two meetings from the listing date on July 6, 2022, to December 31, 2022, and expects to hold at least four meetings annually in the future[153] - The company has implemented a comprehensive risk management policy covering financial reporting, information systems, internal controls, human resources, and investment management[155] - The Board of Directors is responsible for assessing and determining the nature and extent of risks the company is willing to accept, including significant environmental, social, and governance risks[155] - The internal audit department reviewed the internal control system and implemented relevant recommendations to ensure its adequacy and effectiveness[156] - The company has established a whistleblowing and anti-corruption policy to facilitate confidential reporting of misconduct and prevent corruption[157] - The company has adopted a dividend policy that considers factors such as operational performance, financial condition, and capital requirements[159] - The company paid RMB 4,500 thousand in audit fees to KPMG for the reporting period, with no non-audit services provided[162] - The company has a shareholder communication policy and maintains a website (www.cloudr.cn) to provide financial data, corporate governance practices, and other relevant information[165] - The Board of Directors reviewed the shareholder communication policy during the reporting period and ensured its effectiveness[165] Financial Position and Cash Flow - Cash and cash equivalents decreased to RMB 249.7 million as of December 31, 2022, from RMB 1,090.6 million as of December 31, 2021[41] - Financial assets measured at fair value amounted to RMB 423.5 million as of December 31, 2022, primarily for short-term and treasury management purposes[41] - Bank and other loans increased to RMB 192.5 million as of December 31, 2022, from RMB 114.4 million as of December 31, 2021, with an annual interest rate ranging from 3.8% to 5.8%[41] - The company's debt-to-asset ratio was 33.6% as of December 31, 2022, compared to 30.1% as of December 31, 2021[43] - Foreign exchange losses were RMB 459 thousand as of December 31, 2022, compared to RMB 153 thousand as of December 31, 2021[44] - Total employee-related costs were RMB 990.3 million for the year ended December 31, 2022, slightly up from RMB 986.4 million in the previous year[47] - Full-time employee costs decreased to RMB 610.2 million for the year ended December 31, 2022, from RMB 687.7 million in the previous year[47] - Flexible employee costs increased to RMB 380.1 million for the year ended December 31, 2022, from RMB 298.7 million in the previous year[47] - The company had 1,349 full-time employees as of December 31, 2022, with 1,146 in sales and marketing, 135 in R&D, and 68 in general and administrative roles[47] - The company operates primarily in China, with most transactions settled in RMB, and does not engage in significant foreign exchange hedging[44] - The company faces risks related to maintaining revenue growth, profitability, and commercializing solutions, as well as regulatory challenges and trust in its platform[52] - The company's consolidated affiliated entities contributed 2.9% of total revenue and 3.8% of total assets in the reporting period[55] - The company relies on contractual arrangements to control its consolidated affiliated entities, which may not be as effective as direct ownership[57] - Potential non-compliance with Chinese laws and regulations could result in severe penalties or loss of business interests[57] - The company's liquidity and ability to expand may be impacted by Chinese regulations on foreign loans and investments[58] - The company's contractual arrangements may be subject to scrutiny by Chinese tax authorities, potentially leading to additional tax liabilities[58] - The company's business operations could be affected by the Foreign Investment Law[58] - Bankruptcy or dissolution of consolidated affiliated entities could result in loss of critical assets[58] - The company has implemented measures to monitor and mitigate risks related to contractual arrangements, including regular board reviews and external legal consultations[58] - 91 Health Hangzhou and Hangzhou Kangming entered into an Exclusive Consulting Services Agreement on June 16, 2021, which was subsequently amended on October 11, 2021, granting 91 Health Hangzhou exclusive rights to provide various services including technical consulting, IT system support, and business development[59] - The Exclusive Consulting Services Agreement stipulates that Hangzhou Kangming must pay service fees to 91 Health Hangzhou, determined based on factors such as service complexity, time required, and market reference prices[59] - 91 Health Hangzhou holds exclusive intellectual property rights over all developments, whether created by Hangzhou Kangming or 91 Health Hangzhou, and Hangzhou Kangming

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 截至2022年12月31日止年度 年度業績公告 智雲健康科技集團（「本公司」，連同其子公司及併表聯屬實體，統稱「本集團」） 董事（「董事」）會（「董事會」）欣然宣佈本集團截至2022年12月31日止年度（「報告 期」）的年度業績，連同截至2021年12月31日止年度同期的比較數字。該等年度 業績已經本公司審核委員會審閱。 於本公告內，「我們」及「我們的」指本公司，倘文義另有所指，則指本集團。本 公告所載若干金額及百分比數字經過約整，或者四捨五入至小數點後一位或 兩位。任何表格、圖表或其他地方列出的總數及金額總和之間的任何差異均由 約整造成。 – 1 – 財務摘要 附註： | --- | --- | --- | --- | |----------------------------------|--------------------------- ...